ALVO Stock Analysis: Buy, Sell, or Hold?
ALVO - Alvotech Ordinary Shares
$3.14
0.14 (4.67%)
▲
5d:
-8.72%
30d:
-10.8%
90d:
-19.28%
HOLD
LOW Confidence
Analysis Updated: Jun 3, 2026 12:00 AM ET
Earnings: Aug 19, 2026
Get Alerted When ALVO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
1 traders called ALVO this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: ALVO trades at premium valuation expecting 5.1% growth. Hold existing positions but don't chase. Wait for better entry.
📊 HOLD: ALVO trades at premium valuation expecting 5.1% growth. Hold existing positions but don't chase. Wait for better entry.
In-depth Analysis How we analyze
Valuation Analysis: ALVO is currently trading at $3.14, which is considered oversold relative to its 30-day fair value range of $3.24 to $3.52. From a valuation perspective, the stock is trading at a premium (Forward PE: 17.5) compared to its historical average (15.1). At these levels, the market is pricing in 5.1% annual earnings growth.
Technical Outlook: Technically, ALVO is in a strong downtrend. Immediate support is located at $2.94, while resistance sits at $3.50. The stock is showing strong short-term momentum, up 4.7% recently.
Market Sentiment: ALVO has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $13.83 (+340.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, ALVO is in a strong downtrend. Immediate support is located at $2.94, while resistance sits at $3.50. The stock is showing strong short-term momentum, up 4.7% recently.
Market Sentiment: ALVO has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $13.83 (+340.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$3.24 -
$3.52
Company Quality Score
44/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
65.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+4.7%)
- BULLISH: Trading 340.6% below Wall St target ($13.83)
- BULLISH: Expecting earnings turnaround to 5.1% growth with -20.2% revenue growth
- CAUTION: Recommendation downgraded due to -8.7% 5-day decline
Trading Range Analysis
30-Day Trading Range
$3.24 -
$3.52
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$2.94
Resistance Level
$3.50
Current Trend
Strong Downtrend
Technical data as of
Jun 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
17.54
Wall Street Target
$13.83
(+340.6%)
Revenue Growth (YoY)
-20.2%
Earnings Growth (YoY)
-99.1%
Profit Margin
-14.4%
Valuation Premium vs History
+5.1% premium
PE vs Historical
17.5 vs 15.1
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+5.1%
(market-implied from PE analysis)
1-Year Target
$3.30
(+5%)
2-Year Target
$3.47
(+11%)
3-Year Target
$3.65
(+16%)
3-Yr Target (if PE normalizes)
(PE: 18→15)
PE COMPRESSION
$3.14
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.9, Growth: 216.8%)
$13.24
(+322%)
Base:
(SPY PE: 17.5, Growth: 216.8%)
$10.60
(+238%)
Bear:
(PE: 14.9, Growth: 216.8%)
$9.01
(+187%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (34x PE), but valuation improves significantly next year (18x PE) as earnings recover.
Trailing PE: 34.40 | Current EPS (TTM): $0.10
Bull Case
$6.77
(+98%)
Analyst growth 79.0%, PE expands to 37.8
Base Case
$6.16
(+80%)
Market implied 79.0%, PE stable at 34.4
Bear Case
$2.34
(-32%)
Severe decline -20.0%, PE contracts to 29.2
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: June 03, 2026 6:36 PM ET
Data refreshes hourly during market hours. Next update: 7:36 PM
Data refreshes hourly during market hours. Next update: 7:36 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ALVO showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$192 | 66 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$125 | 60 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$104 | 56 HOLD |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 58 HOLD |
|
HCM
HUTCHMED DRC |
STRONG BUY
14 analysts |
$23 | 55 HOLD |
